Nick Joseph

“You mentioned it's a great time to be a buyer. You talked about the attractive, stabilized returns and the timeline for achieving that. Why don't you think you've seen more competition for life science assets?”

“You talked about the robust acquisition pipeline. Obviously, we've seen that come through, you know, in the activity year to date as well as the current pipeline.”

“How are you thinking about the magnitude of the pricing power opportunity for the portfolio? And then what metrics do you focus on to understand pricing power for an individual unit?”

“Jerry, you outlined, obviously, a lot of the progress that you've made over the quarter in the year. I guess just as I think about the capital plan going forward, you mentioned still 5% to 10% to buy back shares.”

“Maybe just on internal growth, you're trending ahead on four-year cash since trying to lie guidance. So just wanted you to touch on the back half assumptions and what is going into the implied deceleration there.”